Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 22, 2002

View Archived Issues

Synaptica and Maybridge enter hit-to-lead optimization collaboration

Novel PDE3 and/or PDE4 inhibitors in Altana development pipeline

Novel compounds for pain and other disorders covered by Gruenenthal patent

Novel antibacterial oxazolidinones under study at Ortho-McNeil

Schering AG presents GnRH antagonists for use in infertility, contraception, etc.

Novel inhibitors of neutral sphingomyelinase in early development at Ono

Otsuka claims new adenosine A3 modulators and their use in glaucoma

Aventis presents new upregulators of eNOS expression

Protein Design Labs to evaluate two Arius anticancer antibodies

Arius and Xerion form colorectal cancer collaboration

Transition Therapeutics' INT enters clinical testing in U.K.

First E.U. trial of DTI-015 cleared to begin in U.K.

Cell Genesys reacquires full commercial rights to GVAX lung cancer vaccines

Highly potent and selective nAChR antagonist related to epibatidine reported in literature

Diaminopyrimidine DHFR inhibitor with promising antibacterial activity

Protection against cisplatin nephrotoxicity in rodents treated with BGP-15

Janssen-Ortho updates safety information for Risperdal in elderly dementia patients

Animal studies demonstrate sustained cocaine-like discriminative stimulus effects of RTI-113

Discovery and CollaGenex team up to develop novel treatments for respiratory diseases

Prous Science invites you to one of the first multipoint "megaconferences" in respiratory medicine

Inhale and Celltech enter licensing, manufacturing and supply agreement for three PEGylated products

Liver histology results for Innogenetics' E1 therapeutic vaccine for HCV

Copaxone approved for seven days room temperature storage in Europe

Centocor expands research and development to focus on immune-mediated inflammatory disorders

PDE5 inhibitor T-1032 effective in hamster model of chronic heart failure

Novartis files sNDA for Zometa showing long-term benefit

Helix to acquire minority interest in Sensium

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...